Several studies have reported the presence of both receptors in normal and cancerous prostate tissues, as well as the loss or down-regulation of ER-β during prostate cancer development (Royuela et al. 2001; Horvath et al. 2001; Leav et al. 2001; Bardin et al. 2004). The gene discussed is ESR2; the disease is prostate carcinoma.